

Exercising of Shareholder Rights – Information December 2022

As a result of the adoption of the “Popular Initiative against Fat-Cat Salaries” in 2014, pension funds have an obligation to exercise shareholder rights in the interests of the insured persons and to disclose how the pension funds voted. This regulation applies for public limited companies with registered office in Switzerland and whose shares are listed on a domestic or foreign stock exchange.

The Foundation Board of the PensUnit Collective Foundation has incorporated the corresponding regulations into the Art. 3.5 of the Organisational Rules or Art. 4 of the Rules on Investment.

A list of the voting record of the PensUnit Collective Foundation in the year 2022 is shown below.



Voting Report

for

Sammelstiftung PensUnit
Kauffmannweg 16
6003 Luzern

This report summarizes voting behaviour according to the following specifications:

Time period: 01.01.2022 - 31.12.2022

Agenda items: Summary of all items on the agenda, i.e. not only the items requiring a vote according to Art. 22 para. 1 ORAb.

The voting rights were exercised for the following companies:


Schaffner	11.01.2022	Zug Estates	12.04.2022
Sika	25.01.2022	Mobimo	12.04.2022
SFS	31.01.2022	Sika	12.04.2022
Novartis	04.03.2022	Julius Bär	12.04.2022
Dätwyler	16.03.2022	Medmix	12.04.2022
DKSH	17.03.2022	Komax	13.04.2022
CPH Chemie + Papier	17.03.2022	Swiss Re	13.04.2022
BB Biotech	17.03.2022	Adecco	13.04.2022
ALSO	18.03.2022	Molecular Partners	13.04.2022
Schindler	22.03.2022	Geberit	13.04.2022
Swiss Prime Site	23.03.2022	Basilea	13.04.2022
Givaudan	24.03.2022	Siegfried	13.04.2022
ABB	24.03.2022	Comet	14.04.2022
Belimo	28.03.2022	Idorsia	14.04.2022
Implenia	29.03.2022	u-blox	20.04.2022
SGS	29.03.2022	Georg Fischer	20.04.2022
Swisscom	30.03.2022	Vetropack	20.04.2022
SenioResidenz	30.03.2022	Flughafen Zürich	21.04.2022
Ina Invest	30.03.2022	Kardex	21.04.2022
Bobst	30.03.2022	Cembra Money Bank	21.04.2022
Inficon	31.03.2022	Arbonia	22.04.2022
PSP Swiss Property	31.03.2022	Swiss Life	22.04.2022
Straumann	05.04.2022	Vifor Pharma	26.04.2022
OC Oerlikon	05.04.2022	Bystronic	26.04.2022
Huber+Suhner	06.04.2022	Alcon	27.04.2022
Sulzer	06.04.2022	Bachem	27.04.2022
Valora	06.04.2022	SFS	27.04.2022
Zurich Insurance Group	06.04.2022	Zur Rose	28.04.2022
Plazza	06.04.2022	APG	28.04.2022
Medartis	06.04.2022	Credit Suisse	29.04.2022
UBS	06.04.2022	Bâloise	29.04.2022
Mobilezone	06.04.2022	EFG International	29.04.2022
Schweiter Technologies	06.04.2022	Helvetia	29.04.2022
Nestlé	07.04.2022	Metall Zug	29.04.2022
Emmi	07.04.2022	Kühne + Nagel	03.05.2022
Rieter	07.04.2022	Cham Group	03.05.2022
Zehnder	07.04.2022	Holcim	04.05.2022
SIG Combibloc	07.04.2022	Von Roll	04.05.2022
TX Group	08.04.2022	Evolva	05.05.2022
Allreal	08.04.2022	Banque Cantonale Vaudoise	05.05.2022
Bossard	11.04.2022	SoftwareONE	05.05.2022
Bucher	12.04.2022	Lonza Group	05.05.2022

Stadler Rail	05.05.2022
Swissquote	06.05.2022
Vaudoise Assurances	09.05.2022
Orascom	10.05.2022
Galenica	11.05.2022
Interroll	13.05.2022
BKW	16.05.2022
VAT Group	17.05.2022
Dufry	17.05.2022
Valiant	18.05.2022
Medacta Group	19.05.2022
Peach Property Group	20.05.2022
Swatch Group	24.05.2022
Temenos	25.05.2022
Partners Group	25.05.2022
Poenina	30.05.2022
Burkhalter	31.05.2022
Private Equity Holding	02.06.2022
HBM Healthcare Investments	10.06.2022
Sonova	15.06.2022
Clariant	24.06.2022
Landis+Gyr	24.06.2022
Ypsomed	29.06.2022
LEM	30.06.2022
Santhera Pharmaceuticals	30.06.2022
Dottikon ES	01.07.2022
Burckhardt Compression	01.07.2022
EMS-Chemie	13.08.2022
Klingelberg	23.08.2022
Dufry	31.08.2022
ABB	07.09.2022
Richemont	07.09.2022
Logitech	14.09.2022
EFG International	06.10.2022
dormakaba	11.10.2022
Valora	14.10.2022
u-blox	21.11.2022
Credit Suisse	23.11.2022
Santhera Pharmaceuticals	29.11.2022
Aryzta	30.11.2022
Barry Callebaut	14.12.2022


Detailed overview

■ Approval ■ Rejection ■ Abstention


Summary




Approval of the management report and the annual and consolidated financial statements




Climate




Shareholder proposals: Climate




Dividend payment




Payout from capital reserves




Par value reduction



Discharge BoD/BoM




Discharge BoD




27 Agenda items
thereof approval: 27
thereof rejection: 0
thereof abstention: 0

Discharge BoM




5 Agenda items
thereof approval: 5
thereof rejection: 0
thereof abstention: 0

Consultative vote on compensation report




91 Agenda items
thereof approval: 48
thereof rejection: 43
thereof abstention: 0

Compensation vote BoD: fixed, prospective




114 Agenda items
thereof approval: 96
thereof rejection: 18
thereof abstention: 0

Compensation vote BoD: fixed, retrospective




7 Agenda items
thereof approval: 5
thereof rejection: 2
thereof abstention: 0

Compensation vote BoD: variable, prospective




2 Agenda items
thereof approval: 1
thereof rejection: 1
thereof abstention: 0

Compensation vote BoD: variable, retrospective




4 Agenda items
thereof approval: 1
thereof rejection: 3
thereof abstention: 0

Compensation vote BoM: fixed, prospective




45 Agenda items
thereof approval: 41
thereof rejection: 4
thereof abstention: 0


Compensation vote BoM: fixed, retrospective




Compensation vote BoM: Variable, prospective




Compensation vote BoM: Variable, Retrospective




Re-election Chairman




Election Chairman




Election of new Board of Directors




Re-election BoD




Re-election Compensation Committee




Election Compensation Committee




Election Independent Proxy




Election of auditor




Ordinary capital increase




Conditional capital: Extension




Conditional capital: Creation




Authorized capital: Extension



Authorized capital: Creation




Capital reduction




17 Agenda items
thereof approval: 15
thereof rejection: 2
thereof abstention: 0

Share buyback programme




4 Agenda items
thereof approval: 4
thereof rejection: 0
thereof abstention: 0

Amendments to the Articles of Incorporation Corporate Governance




19 Agenda items
thereof approval: 16
thereof rejection: 3
thereof abstention: 0

Editorial revision of the Articles of Incorporation




2 Agenda items
thereof approval: 2
thereof rejection: 0
thereof abstention: 0

Other amendments to the Articles of Incorporation




10 Agenda items
thereof approval: 10
thereof rejection: 0
thereof abstention: 0

M&A/restructuring



3 Agenda items
thereof approval: 3
thereof rejection: 0
thereof abstention: 0

Other topics




4 Agenda items
thereof approval: 4
thereof rejection: 0
thereof abstention: 0

Shareholder proposals: Election of the Board of Directors




2 Agenda items
thereof approval: 0
thereof rejection: 2
thereof abstention: 0

Amendments to the Articles of Incorporation ORAb




10 Agenda items
thereof approval: 5
thereof rejection: 5
thereof abstention: 0

Corporate Social Responsibility




1 Agenda items
thereof approval: 1
thereof rejection: 0
thereof abstention: 0

Shareholder proposals: other topics




1 Agenda items
thereof approval: 1
thereof rejection: 0
thereof abstention: 0

Shareholder proposals: Amendments to the Articles of Incorporation Corporate Governance



2 Agenda items
thereof approval: 2
thereof rejection: 0
thereof abstention: 0



1 Agenda items
thereof approval: 1
thereof rejection: 0
thereof abstention: 0